Hepatic encephalopathy (HE) is a spectrum of potentially reversible neuropsychiatric dysfunction caused by liver insufficiency and/or portosystemic shunting, ranging from covert (grades 0–1) to overt (grades 2–4) presentations. [1-2] It is a diagnosis of exclusion — no single test confirms it. Overt HE develops in 30–45% of patients with cirrhosis. [2]
1. History
- Onset and tempo: Acute (hours–days) vs. insidious; episodic, recurrent (>1 episode in 6 months), or persistent [3]
- Symptom characterization: Sleep-wake reversal, shortened attention span, personality changes, bizarre behavior, disorientation, lethargy → somnolence → coma [1-2]
- Precipitant screen (critical): Ask about GI bleeding (hematemesis, melena), recent infections/fevers, constipation, medication changes (new opioids, benzodiazepines, PPIs, diuretics), dietary changes, alcohol use, TIPS placement, and medication nonadherence (especially lactulose/rifaximin) [1][4]
- Important negatives: Headache, seizures, focal weakness (suggest alternative diagnosis); recent falls or head trauma (subdural hematoma risk in coagulopathic patients) [5]
2. Alarm Features
- Grade 3–4 HE: Somnolence, semi-stupor, coma → airway compromise, aspiration risk → ICU [5]
- GCS <8 indicates severe brain injury requiring intubation [5]
- New focal neurological deficits — suggests stroke, intracranial hemorrhage, or mass lesion, not HE [1][5]
- Seizures or first episode of confusion — warrants brain imaging [5]
- No improvement after 48–72 hours of adequate HE therapy → re-evaluate for missed precipitants, alternative diagnoses, or portosystemic shunts [1]
- Multiple concomitant precipitating factors are associated with significantly worse prognosis (in-hospital mortality ~50% in ICU cohorts) [6]
3. Medications
Treatments
- Lactulose (first-line): Acute — 10–20 g (15–30 mL) PO q2h until 2 soft BMs, then 2–4 times daily to maintain 2–3 soft BMs/day. Alternative initial dose: 60 mL followed by 20 mL q1–2h until BM. For grade 3–4 HE: lactulose enema (300 mL lactulose + 700 mL water/NS, retain 30–60 min, q4–6h) [1][5][7]
- PEG 3350: Alternative to lactulose, especially if ileus/abdominal distension; may resolve HE faster than lactulose [1]
- Rifaximin 550 mg PO BID: Add to lactulose for acute OHE (conditional recommendation); standard for secondary prophylaxis (58% risk reduction in recurrence, NNT 4) [1]
- Zinc supplementation: Consider in patients with persistent HE on lactulose + rifaximin who have low zinc levels [1]
- BCAA supplementation: If protein needs cannot be met by food alone [1]
Medications to avoid/use with caution
- Benzodiazepines — precipitate/worsen HE, physical dependence; only short-term at end of life [8-9]
- Opioids — precipitate HE, constipation, respiratory depression [8]
- Sedating antihistamines — worsen HE [8]
- PPIs — associated with increased infection risk in cirrhosis, may precipitate HE [8-9]
- Zolpidem — use with extreme caution, low doses only [8]
- If intubation required: use propofol or dexmedetomidine (short half-lives) [5]
4. Diet
- No protein restriction — protein restriction increases muscle breakdown and does not reduce HE duration [1][10]
- Protein target: 1.2–1.5 g/kg/day, preferably from diverse sources including vegetable/dairy protein [1][11]
- Caloric target: 30–40 kcal/kg/day [7][12]
- Late-night snack recommended — overnight fasting exacerbates catabolism and may worsen HE [1][7]
- Vegetable-based protein may be preferable (higher arginine/fiber content, lower ammonia production) [13]
- Adequate hydration — dehydration is a common precipitant [1]
- Distribute intake across 4–6 small meals daily; minimize fasting intervals to 3–4 hours [11-12]
5. Review of Systems
- Neuro: Sleep disturbance, day-night reversal, concentration difficulty, personality changes, tremor, gait instability, falls [1][7]
- GI: Hematemesis, melena, hematochezia, abdominal distension, constipation, nausea [1]
- Infectious: Fever, chills, dysuria, cough, abdominal pain (SBP) [1]
- Psych: Depression, anxiety, irritability, bizarre behavior [1]
- Constitutional: Fatigue, weight loss, anorexia [7]
6. Collateral History and Family History
- Collateral is essential — patients with HE often cannot provide reliable history; interview caregivers/family about baseline cognition, medication adherence (especially lactulose), alcohol/substance use, recent dietary changes, and timeline of mental status changes [8]
- Medication reconciliation — verify lactulose adherence (most common cause of breakthrough HE is nonadherence or dehydration) [1]
- Family history: Hereditary liver diseases (Wilson disease, hemochromatosis, alpha-1 antitrypsin deficiency) if etiology of cirrhosis is unclear
- Social context: Caregiver availability, driving status (covert HE increases motor vehicle accident risk), advance care planning [2][8]
7. Risk Factors
- Cirrhosis (any etiology) — alcohol-associated, viral hepatitis, MASLD/MASH, autoimmune [3][14]
- Prior HE episodes — strongest predictor of recurrence [1]
- TIPS placement — HE develops in 10–50% post-TIPS [2]
- Spontaneous portosystemic shunts (SPSS) — present in 46–71% of refractory HE cases [1]
- Sarcopenia/malnutrition — skeletal muscle is an alternative ammonia detoxification site; loss increases HE risk [12]
- Higher MELD/Child-Pugh scores [6]
- Precipitant exposure: Infections (most common cause of hospitalization in cirrhosis), GI bleeding, constipation, dehydration, diuretic overuse, hyponatremia, sedating medications [1][4]
8. Differential Diagnosis
The following figure illustrates the broad differential for altered mental status in cirrhotic patients:
- Alcohol intoxication/withdrawal (including Wernicke encephalopathy) — common coexistence [5]
- Intracranial hemorrhage (subdural, subarachnoid) — cirrhotic patients are coagulopathic and fall-prone [1]
- Stroke [1]
- Metabolic encephalopathy: Uremia, hypoglycemia/hyperglycemia, DKA, hyperosmolar state, hyponatremia, hypoxia [1][5]
- Sepsis/infection — can both mimic and precipitate HE [1]
- Drug-related: Opioids, benzodiazepines, sedatives [9]
- Nonconvulsive status epilepticus [1]
- Psychiatric disorders [5]
- Dementia/neurodegenerative disease (especially in elderly) [16]
Pearl: Asterixis is not pathognomonic — it can also be seen in uremic and other metabolic encephalopathies. [1]
9. Past Medical History
- Etiology and duration of liver disease; Child-Pugh/MELD score
- Prior HE episodes (number, frequency, precipitants, response to treatment)
- TIPS placement or known portosystemic shunts
- Variceal bleeding history
- Ascites and SBP history
- Hepatocellular carcinoma screening status
- Comorbidities: CKD, diabetes, heart failure (cirrhotic cardiomyopathy)
- Transplant candidacy status
10. Physical Exam
- Vitals: Hypotension (sepsis, GI bleed), tachycardia, fever (infection), hypoxia
- Neuro: Grade using West Haven Criteria and GCS: [1][5]
- Asterixis: Elicit with wrists hyperextended — present in grade 2, may be absent in grade 3–4 [1]
- Focal deficits: If present, HE is less likely → pursue brain imaging [1]
- Stigmata of chronic liver disease: Jaundice, spider angiomata, palmar erythema, gynecomastia, caput medusae, ascites, splenomegaly
- Signs of precipitants: Peritonitis (SBP), cellulitis, pneumonia, GI bleeding (rectal exam)
11. Lab Studies
Recommended labs (to identify precipitants, not to diagnose HE):
- CBC, CMP (BUN/Cr, electrolytes including Na, glucose), LFTs, INR
- Blood cultures, urinalysis/urine culture
- Diagnostic paracentesis in all hospitalized patients with ascites (rule out SBP: PMN >250/μL) [1][7]
- Lactate, blood gas if sepsis suspected
- Drug/alcohol screen, medication levels as indicated
- Stool guaiac or stool studies if GI bleed suspected
Ammonia
- Not routinely recommended for diagnosis or treatment titration [1][5]
- A normal ammonia in a stuporous/comatose patient should prompt investigation of alternative diagnoses [1][5]
- 40% of patients diagnosed with HE have normal ammonia levels [1]
- Ammonia levels do not correlate with HE severity and are unreliable due to sample handling issues [1]
12. Imaging
- Routine brain imaging is NOT warranted in patients with recurrent, nonfocal HE presentations similar to prior episodes [1][5]
- Brain CT indicated if: First episode of confusion, new focal neurological deficits, seizures, history of fall/head trauma, or failure to respond to 48–72 hours of adequate HE therapy [1][5]
- Cross-sectional imaging (CT/MRI abdomen): Consider if evaluating for portosystemic shunts (TIPS patency, SPSS) in refractory HE [1]
- Chest X-ray: If infection suspected as precipitant
13. Special Tests
- West Haven Criteria — standard grading tool for HE severity [1][5]
- Glasgow Coma Scale — for patients with significant impairment of consciousness (GCS <8 = severe) [5]
- Animal Naming Test: <10 animals in 60 seconds → high specificity (92%) for covert HE [2][7]
- EncephalApp Stroop Test: >198 seconds → 80% sensitivity for covert HE [7]
- Psychometric Hepatic Encephalopathy Score (PHES): Gold standard for covert HE (5-test paper-pencil battery) [7][14]
- EEG: Consider if nonconvulsive status epilepticus suspected in nonresponders [1]
- Diagnostic paracentesis: All hospitalized cirrhotics with ascites [7]
14. ECG
- QTc prolongation is present in approximately 50% of cirrhotic patients (cirrhotic cardiomyopathy) [17-18]
- Obtain ECG to assess for QTc prolongation, especially before prescribing QT-prolonging medications (ondansetron, citalopram, haloperidol, metoclopramide) [8]
- Electrophysiological abnormalities include prolonged QTc, electrical dyssynchrony, and chronotropic incompetence [17][19]
- T-wave axis abnormalities and altered repolarization patterns may be seen [20]
- ECG also useful to evaluate for arrhythmias in the setting of electrolyte derangements (hypokalemia, hypomagnesemia from lactulose overuse or diuretics)
15. Assessment
- HE is a clinical diagnosis of exclusion based on history, exam, and West Haven grading in a patient with known or suspected cirrhosis [1][7]
- Severity stratification drives disposition: Grade 1 → outpatient; Grade 2 → floor; Grade 3–4 → step-down/ICU [1][5]
- Always pursue a precipitant — infections are the most common cause of hospitalization in cirrhosis and a leading HE trigger [1]
- Atypical presentations: Covert HE may present as falls, gait disturbance, poor sleep quality, or impaired driving ability without overt confusion [7]
- Complications: Aspiration pneumonia, falls/injuries, persistent cognitive impairment, progression to ACLF; all-cause mortality approaches 50% in hospitalized patients with severe HE [3]
16. Treatment Plan
Initial stabilization (concurrent steps)
- Airway protection — intubate if GCS <8 or unable to protect airway [5][9]
- IV hydration — correct dehydration/hypovolemia [7]
- Identify and treat precipitants — pan-culture, diagnostic paracentesis, correct electrolytes, hold offending medications [1]
HE-specific therapy
- Lactulose PO: 15–30 mL q2h until 2 soft BMs → then titrate to 2–3 soft BMs/day [1]
- Lactulose enema (grade 3–4 or unable to swallow): 300 mL lactulose + 700 mL water/NS, retain 30–60 min, q4–6h [1][5]
- PEG 3350 (4L): Alternative if ileus, abdominal distension, or lactulose intolerance; may resolve HE faster [1]
- Add rifaximin 550 mg PO BID to lactulose for acute OHE (combination reduces mortality and hospital stay vs. lactulose alone) [1][21]
- Thiamine — administer empirically before glucose if Wernicke suspected [22]
The following figure outlines a management algorithm for acute overt HE:
Secondary prophylaxis (at discharge)
- Lactulose titrated to 2–3 soft BMs/day (strong recommendation) [1]
- Rifaximin 550 mg PO BID — add after first episode of OHE, especially if recurrence on lactulose alone (strong recommendation for recurrent HE) [1]
- Zinc supplementation if levels low and persistent symptoms on dual therapy [1]
- Medication reconciliation — discontinue/reduce sedating medications [1]
17. Disposition
- ICU/step-down: Grade 3–4 HE, GCS <8, hemodynamic instability, active GI bleeding, respiratory compromise [5]
- Floor admission: Grade 2 HE, need for IV lactulose/enemas, active precipitant requiring treatment (infection, electrolyte correction) [1]
- Observation/short stay: Mild grade 2 HE with rapidly identifiable and treatable precipitant, improving with lactulose
- Discharge criteria: Return to baseline mental status, tolerating oral lactulose, precipitant addressed, caregiver education completed, outpatient follow-up arranged [1]
- GI/Hepatology consult: Refractory HE (no improvement at 48–72h), first episode without known cirrhosis, evaluation for TIPS revision or shunt embolization, transplant evaluation [1]
18. Follow Up / Return Precautions
- Follow-up: Hepatology/GI within 1–2 weeks of discharge; PCP within 7 days [1]
- Medication adherence counseling: Lactulose titration using Bristol Stool Scale (target score ~4), rifaximin compliance [1]
- Return precautions — instruct patient/caregiver to return for:
- Recurrent confusion, disorientation, or excessive somnolence
- Fever, abdominal pain, or signs of infection
- GI bleeding (hematemesis, melena, bloody stool)
- Inability to tolerate lactulose or >1 day without bowel movement
- Falls or new weakness
- Driving: Patients with covert HE are at increased risk of motor vehicle accidents — counsel accordingly [2]
- Expected course: Episodes are typically reversible with treatment, but recurrence is common (~42% recurrence rate); each episode may leave residual cognitive impairment [3][6]
- Advance care planning: Identify surrogate decision-maker before onset of severe HE [8]
References
1. ACG Clinical Guideline: Hepatic Encephalopathy. — Bajaj JS, Jakab SS, Jesudian AB, et al. The American Journal of Gastroenterology. 2026.
2. Liver Cirrhosis. — Ginès P, Krag A, Abraldes JG, et al. Lancet. 2021.
3. Branched-Chain Amino Acids for People With Cirrhosis and Hepatic Encephalopathy. — Aamann L, Deshpande N, Dam G, et al. The Cochrane Database of Systematic Reviews. 2026.
4. Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution. — Bellafante D, Gioia S, Faccioli J, et al. Journal of Clinical Medicine. 2023.
5. AASLD Practice Guidance on Acute-on-Chronic Liver Failure and the Management of Critically Ill Patients With Cirrhosis. — Karvellas CJ, Bajaj JS, Kamath PS, et al. Hepatology. 2024.
6. Multiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit. — Rudler M, de Matharel M, Bouzbib C, et al. United European Gastroenterology Journal. 2025.
7. Diagnosis and Management of Cirrhosis and Its Complications: A Review. — Tapper EB, Parikh ND. The Journal of the American Medical Association. 2023.
8. AASLD Practice Guidance: Palliative Care and Symptom-Based Management in Decompensated Cirrhosis. — Rogal SS, Hansen L, Patel A, et al. Hepatology. 2022.
9. Acute-on-Chronic Liver Failure Clinical Guidelines. — Bajaj JS, O'Leary JG, Lai JC, et al. The American Journal of Gastroenterology. 2022.
10. Hepatic Encephalopathy. — Wijdicks EF. The New England Journal of Medicine. 2016.
11. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. — Lai JC, Tandon P, Bernal W, et al. Hepatology. 2021.
12. Nutrition Assessment and Management in Patients With Cirrhosis and Cognitive Impairment: A Comprehensive Review of Literature. — Faccioli J, Nardelli S, Gioia S, Riggio O, Ridola L. Journal of Clinical Medicine. 2022.
13. ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. — Singal AK, Wong RJ, Dasarathy S, et al. The American Journal of Gastroenterology. 2025.
14. Aminoglycosides, Vancomycin, and Metronidazole for People With Cirrhosis and Hepatic Encephalopathy. — Jeyaraj R, Zacharias HD, Vadera S, et al. The Cochrane Database of Systematic Reviews. 2026.
15. Review article: Evaluation and care of the critically ill patient with cirrhosis. — Kosuta I, Premkumar M, Reddy KR. Alimentary Pharmacology & Therapeutics. 2024.
16. Considerations in the Diagnoses and Management of Hepatic Disease in Older Adults. — Brown CL, Bajaj JS. The American Journal of Gastroenterology. 2025.
17. Cirrhotic Cardiomyopathy: The Liver Affects the Heart. — Carvalho MVH, Kroll PC, Kroll RTM, Carvalho VN. Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas. 2019.
18. Cirrhotic Cardiomyopathy. — Møller S, Henriksen JH. Journal of Hepatology. 2010.
19. Cardiovascular Risk Assessment of the Liver Transplant Candidate. — Raval Z, Harinstein ME, Skaro AI, et al. Journal of the American College of Cardiology. 2011.
20. Electrocardiogram-Based Diagnosis of Liver Diseases: An Externally Validated and Explainable Machine Learning Approach. — Lopez Alcaraz JM, Haverkamp W, Strodthoff N. EClinicalMedicine. 2025.
21. Combination Therapy With Rifaximin and Lactulose in Hepatic Encephalopathy: A Systematic Review and Meta-Analysis. — Fu J, Gao Y, Shi L. PloS One. 2022.
22. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. — Vilstrup H, Amodio P, Bajaj J, et al. Hepatology. 2014.
23. Hepatic Encephalopathy: Classification, Diagnosis, and Treatment. — Radha K. Dhiman, Sahaj Rathi Evidence‐based Gastroenterology and Hepatology 4e. 2019.